Comparative Pharmacology
Head-to-head clinical analysis: CARGLUMIC ACID versus OLPRUVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARGLUMIC ACID versus OLPRUVA.
CARGLUMIC ACID vs OLPRUVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carglumic acid is a structural analog of N-acetylglutamate (NAG) and acts as a replacement for NAG in the urea cycle. It activates carbamoyl phosphate synthetase 1 (CPS1), the first enzyme of the urea cycle, by binding to the allosteric site that normally binds NAG, thereby promoting the conversion of ammonia to urea and reducing hyperammonemia.
Olprinone is a selective phosphodiesterase III (PDE3) inhibitor, which increases intracellular cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle cells, leading to positive inotropic and vasodilatory effects.
100-250 mg/kg/day orally, divided into 3-4 doses, maximum 250 mg/kg/day.
2 mg orally three times daily with meals or as directed by physician
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in adults; prolonged in renal impairment
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged in renal impairment (up to 40 hours in severe impairment).
Primarily renal (approximately 80% as unchanged drug); minor biliary/fecal elimination (<5%)
Primarily renal excretion as unchanged drug (approximately 70%) and glucuronide conjugate (approximately 15%); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Urea Cycle Disorder Agent
Urea Cycle Disorder Agent